← Eichor
Study identifier: NCT06767800 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Condition: Gastroesophageal Adenocarcinoma  ·  Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

PhasePhase 2
Planned participants204
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

TQB2102 for injection is a novel antibody-coupled drug (ADC) that enhances binding to tumor cell surface HER2 proteins by simultaneously targeting the two non-overlapping epitopes of the HER2 protein, Endothelial Cell Dysfunction 2 (ECD2) and Endothelial Cell Dysfunction 4 (ECD4), increasing HER2 internalization, and then down-regulating the tumor cell surface HER2 proteins more effectively, and doubly blocking the HER2 signaling, to achieve the effects of trastuzumab and Pertuzumab alone and in combination. This is a Phase II study to evaluate the efficacy and safety of TQB2102 for injection in combination with Benmelstobart Injection /Penpulimab Injection ± chemotherapy in patients with unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Ruihua Xu, Doctor  ·  86-20-87343468  ·  ruihxu@163.com

Always discuss trial participation with your own doctor first.

Locations (39)

Fuyang Cancer HospitalFuyang, Anhui, ChinaNot Yet Recruiting
Lu'an People's HospitalLu'an, Anhui, ChinaNot Yet Recruiting
Maanshan People's HospitalMaanshan, Anhui, ChinaRecruiting
Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaNot Yet Recruiting
The first affiliated hospital of chongqing medical universityChongqing, Chongqing Municipality, ChinaNot Yet Recruiting
Fujian Cancer HospitalFuzhou, Fujian, ChinaNot Yet Recruiting
Gansu Prouincial Cancer HospitalLanzhou, Gansu, ChinaNot Yet Recruiting
Gansu Wuwei Tumour HospitalWuwei, Gansu, ChinaNot Yet Recruiting
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaNot Yet Recruiting
Nanfang HospitalGuangzhou, Guangdong, ChinaNot Yet Recruiting
Jiangmen Central HospitalJiangmen, Guangdong, ChinaNot Yet Recruiting
Meizhou People's HospitalMeizhou, Guangdong, ChinaNot Yet Recruiting

+ 27 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06767800